The Ozempic Semaglutide Pen: Licence, Use and What It Means for Weight Loss

What the clinical evidence actually says about semaglutide injections

The evidence base for semaglutide as a weight-management medicine is built on the STEP programme, a series of large phase 3 trials that tested the 2.4mg weekly dose specifically in adults with obesity or overweight. The STEP 1 trial, published in the New England Journal of Medicine, randomised 1,961 adults without diabetes and found an average body-weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose, alongside lifestyle changes. That is the evidence underpinning Wegovy's licence, not the lower doses used in Ozempic for diabetes.

Ozempic's clinical trials were designed to demonstrate blood-sugar control in type 2 diabetes, with weight loss as a secondary finding. The MHRA has licensed each product on the basis of the trials submitted for that specific indication. Prescribing Ozempic for weight loss would be off-label use, meaning the medicine is being used outside the terms its licence was granted on. That is a meaningful clinical and regulatory distinction, not a technicality.

The NHS semaglutide medicines page sets out both products clearly, which is a useful starting point if you want to read the official patient-level information alongside what is written here.

How the ozempic semaglutide injection actually works, and why dose matters

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a gut hormone released after eating, and acts on receptors in the brain, gut and pancreas to reduce appetite, slow how quickly the stomach empties and improve blood-sugar regulation. That mechanism is the same whether the pen says Ozempic or Wegovy. What differs is the dose.

Ozempic comes in 0.5mg, 1mg and 2mg weekly maintenance doses, titrated from a starting dose of 0.25mg. Wegovy's maintenance dose is 2.4mg (higher than any licensed Ozempic dose) and in April 2026 the MHRA approved a dedicated single-dose 7.2mg Wegovy semaglutide pen as the maximum dose for adults with obesity. If you want to understand whether semaglutide and Ozempic refer to the same thing, the short answer is that semaglutide is the molecule and Ozempic is one brand of it, a brand built around a diabetes dose, not a weight-management one.

For anyone considering the semaglutide ozempic pen as a weight-loss tool, it is worth knowing that the 2.4mg dose in Wegovy was not an arbitrary choice. The STEP trials showed a dose-response relationship, higher doses produced greater average weight reduction. Using a lower, diabetes-licensed dose would not replicate the weight-management results seen in those trials.

What is actually licensed for weight loss in the UK, and how to access it

Two injectable medicines currently hold UK MHRA licences for weight management in adults. Wegovy (semaglutide 2.4mg) is a once-weekly injection approved for adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition. Mounjaro (tirzepatide) is a once-weekly dual GIP and GLP-1 receptor agonist with a separate licence covering the same BMI criteria. In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks. Both medicines are Black Triangle products under additional MHRA monitoring.

Ozempic does not appear on that list. Neither does Rybelsus, the oral semaglutide tablet licensed for type 2 diabetes, not weight management. If you have been reading about Ozempic in the context of weight loss, you will likely have encountered a good deal of confusion between the two products. That confusion is understandable; the molecule is the same. The licences are not.

Accessing Wegovy legally in the UK means a prescription following a clinical assessment. The NHS route exists but carries strict phased eligibility criteria and, in many areas, a long wait. Private prescribing through a GPhC-registered online pharmacy is the alternative. You can verify any pharmacy's registration on the GPhC register before engaging with them, it takes about thirty seconds and is the simplest check you can run.

If cost is part of your thinking, the weight-loss treatment overview covers what private treatment typically includes and how pricing is structured for licensed medicines in the UK.

Injection technique, side effects and what to expect with semaglutide pens

The subcutaneous injection technique for Wegovy is broadly similar to what patients using the ozempic semaglutide injection for type 2 diabetes will already know: the injection goes under the skin of the abdomen, thigh or upper arm, rotating sites each week. The pen is pre-filled; detailed technique guidance is in the Patient Information Leaflet supplied with the medicine, and your prescriber or pharmacist can answer questions specific to your situation. Practical detail on the pen's format (whether needles are included, how the mechanism works) is covered on the Wegovy needles page.

Side effects of semaglutide are predominantly gastrointestinal: nausea, vomiting, diarrhoea and constipation are most commonly reported, especially in the weeks after starting or after a dose increase. They tend to settle as the body adjusts. More detail on the side-effect profile is on the semaglutide side effects page, including the symptoms that need prompt medical attention. One of those is severe, persistent stomach pain that radiates to the back, a possible sign of acute pancreatitis, which the MHRA highlighted as a known but infrequent risk in its January 2026 Drug Safety Update for GLP-1 medicines. If that symptom develops, seek urgent medical help rather than waiting.

Used sharps require proper disposal. A sharps container keeps used pens and needles safe until they can be collected or returned to a pharmacy.

If you think Wegovy might be suitable for you, our prescribers at nume carry out a same-day clinical review, a real person reads your consultation, not software. Check your eligibility by starting a free consultation.